Literature DB >> 2184068

Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans.

A Ceriello1, D Giugliano, A Quatraro, E Marchi, M Barbanti, P Lefèbvre.   

Abstract

In the presence of increased levels of fibrinopeptide A, decreased antithrombin III biological activity, and thrombin-antithrombin III complex levels are seen in diabetic patients. Induced-hyperglycaemia in diabetic and normal subjects decreased antithrombin III activity and thrombin-antithrombin III levels, and increased fibrinopeptide A plasma levels, while antithrombin III concentration did not change; heparin was shown to reduced these phenomena. In diabetic patients, euglycaemia induced by insulin infusion restored antithrombin III activity, thrombin-antithrombin III complex and fibrinopeptide A concentrations; heparin administration had the same effects. These data stress the role of a hyperglycaemia-dependent decrease of antithrombin III activity in precipitating thrombin hyperactivity in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184068     DOI: 10.1007/bf00404044

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin.

Authors:  M J Griffith
Journal:  J Biol Chem       Date:  1982-07-10       Impact factor: 5.157

4.  Hyperglycemia may determine fibrinopeptide A plasma level increase in humans.

Authors:  A Ceriello; D Giugliano; A Quatraro; P Dello Russo; E Marchi; R Torella
Journal:  Metabolism       Date:  1989-12       Impact factor: 8.694

5.  Evidence for the formation of an ester between thrombin and heparin cofactor.

Authors:  W G Owen
Journal:  Biochim Biophys Acta       Date:  1975-10-20

6.  Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation.

Authors:  A Ceriello; D Giugliano; A Quatraro; A Stante; G Consoli; P Dello Russo; F D'Onofrio
Journal:  Diabete Metab       Date:  1987-02

7.  Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects.

Authors:  A Ceriello; D Giugliano; A Quatraro; G Consoli; A Stante; P Dello Russo; F D'Onofrio
Journal:  Diabetes       Date:  1987-03       Impact factor: 9.461

8.  The fluid phase of coagulation and the accelerated atherosclerosis of diabetes mellitus.

Authors:  R L Jones; C M Peterson
Journal:  Diabetes       Date:  1981       Impact factor: 9.461

9.  Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics.

Authors:  A Ceriello; D Giugliano; A Quatraro; A Stante; G Consoli; P Dello Russo; F D'Onofrio
Journal:  Haemostasis       Date:  1986

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  7 in total

Review 1.  Pathogenesis of diabetic cerebral vascular disease complication.

Authors:  Ren-Shi Xu
Journal:  World J Diabetes       Date:  2015-02-15

Review 2.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

Review 3.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 4.  Should all diabetic patients receive statins?

Authors:  Paul J Garcia; Craig W Spellman
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

Review 5.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.

Authors:  A Ceriello
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

Review 6.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Interleukin-1-beta and dyslipidemic syndrome as major risk factors for thrombotic complications in type 2 diabetes mellitus.

Authors:  Oana Bădulescu; Codruţa Bădescu; Manuela Ciocoiu; Magda Bădescu
Journal:  Mediators Inflamm       Date:  2013-01-21       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.